8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), 19 – 22 July 2015, Vancouver, Canada
The 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) was held from 19 – 22 July 2015.
This large biennial meeting has a greater focus on clinical and scientific research than the broader social-based programme of the International AIDS Conference with which it alternates every two years.
The programme for the conference is now posted to the IAS 2015 website as PDF files and the Programme-at-a-Glance (PAG) is also online.
Many oral presentations are available as webcasts, including some plenary lectures, special symposia, oral abstract sessions and the opening and closing ceremonies. But coverage seems less than previous years and this is a pity. Many of the PowerPoint slides from talks and PDF files of posters are online.
Although currently access to the this material is predominantly through the online programme-at-a-glace, for those who find navigation takes slightly longer, i-Base have published a short access guide.
Unfortunately, URL hyperlinks to individual abstracts are not available with the current PAG. This is likely to limit practical access to this otherwise important aspect of the conference.
Reports in the issue:
- Tribute to Bob Munk: long-time HIV positive US treatment activist and educator
- Four reasons IAS 2015 will be a milestone HIV conference: a personal view
- Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study
- The option for same day ART on diagnoses: the future for HIV care
- Pipeline ARVs at IAS 2015: doravirine, BMS-955176 and BMS-663068
- New directions in the 2015 WHO ART guidelines
- Rapid implementation of the 2013 WHO ART guidelines
- Large variation across countries in meeting UNAIDS 90-90-90 targets
- Low dose boosted atazanavir is non-inferior to standard dose in Thai treatment optimisation study: LASA
- HPTN 052: no HIV transmissions on effective ART – but limited data on viral failure and drug resistance
- Dispersible tablet formulation of dolutegravir is bioequivalent to the granule formulation
- New case of remission in a perinatally infected teenager
- IAS 2015: accessing online webcasts and abstracts